KR20170045748A - 증식성 질병의 치료를 위한 조성물 및 방법 - Google Patents

증식성 질병의 치료를 위한 조성물 및 방법 Download PDF

Info

Publication number
KR20170045748A
KR20170045748A KR1020177008846A KR20177008846A KR20170045748A KR 20170045748 A KR20170045748 A KR 20170045748A KR 1020177008846 A KR1020177008846 A KR 1020177008846A KR 20177008846 A KR20177008846 A KR 20177008846A KR 20170045748 A KR20170045748 A KR 20170045748A
Authority
KR
South Korea
Prior art keywords
cancer
cell
compound
composition
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
KR1020177008846A
Other languages
English (en)
Korean (ko)
Inventor
다니엘 티 드란스필드
수드하샨 이티라즈
장-마르크 라피에르
브라이언 슈왈츠
이 유
Original Assignee
아르퀼 인코포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 아르퀼 인코포레이티드 filed Critical 아르퀼 인코포레이티드
Publication of KR20170045748A publication Critical patent/KR20170045748A/ko
Abandoned legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Steroid Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Epoxy Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicinal Preparation (AREA)
KR1020177008846A 2014-09-05 2015-09-04 증식성 질병의 치료를 위한 조성물 및 방법 Abandoned KR20170045748A (ko)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201462046502P 2014-09-05 2014-09-05
US62/046,502 2014-09-05
US201462082236P 2014-11-20 2014-11-20
US62/082,236 2014-11-20
PCT/US2015/048520 WO2016037044A1 (en) 2014-09-05 2015-09-04 Compositions and methods for treating proliferation disorders

Publications (1)

Publication Number Publication Date
KR20170045748A true KR20170045748A (ko) 2017-04-27

Family

ID=55436479

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020177008846A Abandoned KR20170045748A (ko) 2014-09-05 2015-09-04 증식성 질병의 치료를 위한 조성물 및 방법

Country Status (14)

Country Link
US (1) US9949981B2 (https=)
EP (1) EP3189036B1 (https=)
JP (2) JP6574245B2 (https=)
KR (1) KR20170045748A (https=)
CN (2) CN111494378A (https=)
AU (2) AU2015311751B2 (https=)
BR (1) BR112017004459A2 (https=)
CA (1) CA2958770A1 (https=)
ES (1) ES2955926T3 (https=)
IL (2) IL250715B (https=)
MX (1) MX382891B (https=)
RU (2) RU2019142694A (https=)
SG (1) SG11201701704XA (https=)
WO (1) WO2016037044A1 (https=)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20230156450A (ko) 2012-10-15 2023-11-14 에피자임, 인코포레이티드 암을 치료하는 방법
WO2017035234A1 (en) 2015-08-24 2017-03-02 Epizyme, Inc. Method for treating cancer
US11561226B2 (en) 2016-03-14 2023-01-24 Pierce Biotechnology Inc. Detection and quantification of AKT-mTOR pathway proteins
WO2018013430A2 (en) 2016-07-12 2018-01-18 Arisan Therapeutics Inc. Heterocyclic compounds for the treatment of arenavirus infection
US20190350929A1 (en) * 2017-02-02 2019-11-21 Epizyme, Inc. Cancer treatment modalities
WO2019071171A1 (en) * 2017-10-05 2019-04-11 The Board Of Trustees Of The University Of Illinois Method of treating sickle cell disease
CN110669015A (zh) * 2018-07-03 2020-01-10 上海喀露蓝科技有限公司 一种fgfr抑制剂的制备方法
EP3880202A2 (en) * 2018-11-16 2021-09-22 ArQule, Inc. Pharmaceutical combination for treatment of cancer
US12419865B2 (en) 2018-12-06 2025-09-23 Arisan Therapeutics Inc. Compounds for the treatment of arenavirus infection
PL3919491T3 (pl) * 2019-01-29 2025-10-20 Nanjing Chia Tai Tianqing Pharmaceutical Co., Ltd. Inhibitor akt
US20220184147A1 (en) * 2019-03-04 2022-06-16 Northwestem University Bacterial enzymatic conversion of anthracycline chemotherapeutics to reduce toxicity and promote diversity among the intestinal microbiota
WO2022053708A1 (en) * 2020-09-14 2022-03-17 Basilea Pharmaceutica International AG Pharmaceutical combinations for use in the treatment of gastric adenocarcinoma
IL301567A (en) * 2020-09-30 2023-05-01 Chia Tai Tianqing Pharmaceutical Group Co Ltd A compound as an AKT KINASE inhibitor
CN112225745B (zh) * 2020-11-16 2021-10-12 烟台大学 一种具有抗肿瘤活性的异片螺素类化合物、制备方法及用途
EP4486390A1 (en) * 2022-03-02 2025-01-08 Terremoto Biosciences, Inc Covalent modifiers of akt1 and uses thereof
WO2025034613A1 (en) * 2023-08-04 2025-02-13 Terremoto Biosciences, Inc. 3h-imidazo[4,5-b]pyridine compounds as non-covalent modifiers of akt1 and uses thereof

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010078430A1 (en) * 2008-12-30 2010-07-08 Arqule, Inc. Substituted 1h-pyrazolo[3,4-d]pyrimidine-6-amine compounds
TWI461410B (zh) * 2008-12-30 2014-11-21 Arqule Inc 經取代之５，６－二氫－６－苯基苯並〔f〕異喹啉－２－胺化合物類
EP2414358A1 (en) * 2009-03-31 2012-02-08 ArQule, Inc. Substituted tetrahydropyrazolo-pyrido-azepin compounds
DK2519522T3 (en) * 2009-12-30 2014-12-08 Arqule Inc SUBSTITUTED IDAZOPYRIDINYL AMINOPYRIDINE COMPOUNDS
KR20190015600A (ko) 2011-06-24 2019-02-13 아르퀼 인코포레이티드 치환된 이미다조피리디닐-아미노피리딘 화합물
US8815854B2 (en) 2011-06-24 2014-08-26 Arqule, Inc. Substituted imidazopyridinyl compounds

Also Published As

Publication number Publication date
CN111494378A (zh) 2020-08-07
WO2016037044A1 (en) 2016-03-10
CN107074769A (zh) 2017-08-18
ES2955926T3 (es) 2023-12-11
MX2017002892A (es) 2017-06-06
RU2711500C2 (ru) 2020-01-17
MX382891B (es) 2025-03-13
IL250715B (en) 2020-09-30
EP3189036B1 (en) 2023-07-19
RU2017111204A (ru) 2018-10-05
AU2020203706B2 (en) 2022-01-13
BR112017004459A2 (pt) 2017-12-05
CA2958770A1 (en) 2016-03-10
RU2019142694A (ru) 2020-02-26
AU2015311751A1 (en) 2017-03-09
IL277028A (en) 2020-10-29
JP6837525B2 (ja) 2021-03-03
US20160067260A1 (en) 2016-03-10
EP3189036A4 (en) 2018-04-04
RU2017111204A3 (https=) 2019-03-25
EP3189036A1 (en) 2017-07-12
IL250715A0 (en) 2017-04-30
JP2017526698A (ja) 2017-09-14
AU2020203706A1 (en) 2020-06-25
AU2015311751B2 (en) 2020-03-12
CN107074769B (zh) 2020-04-07
US9949981B2 (en) 2018-04-24
SG11201701704XA (en) 2017-04-27
JP6574245B2 (ja) 2019-09-11
JP2020002148A (ja) 2020-01-09

Similar Documents

Publication Publication Date Title
JP6837525B2 (ja) 増殖性障害を処置するための組成物および方法
KR101689421B1 (ko) 치환된 이미다조피리디닐-아미노피리딘 화합물
KR101974673B1 (ko) 치환된 이미다조피리디닐-아미노피리딘 화합물
ES2886099T3 (es) Compuestos de benceno sustituidos con arilo o heteroarilo
JP5739820B2 (ja) 置換５，６−ジヒドロ−６−フェニルベンゾ［ｆ］イソキノリン−２−アミン化合物
US8541407B2 (en) Substituted benzo-pyrido-triazolo-diazepine compounds
JP2013516420A (ja) 置換されたピロロ−アミノピリミジン化合物
TW201313710A (zh) 經取代之咪唑並吡啶基化合物
JP2023504866A (ja) 大環構造を有するフッ素含有複素環誘導体およびその用途
TW201139410A (en) Substituted naphthalenyl-pyrimidine compounds
TW201307347A (zh) 經取代苯並－咪唑並－吡啶並－二氮呯化合物
JP5984837B2 (ja) ピロロキノリニル−ピロリジン−２，５−ジオン組成物ならびにそれを調製および使用する方法
CN107056754B (zh) 内嵌脲类结构的wnt通路抑制剂
WO2023082044A1 (zh) 5-醛基杂环酰胺类化合物及其应用
HK40051951B (zh) 杂环化合物

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20170331

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20200826

Comment text: Request for Examination of Application

PC1902 Submission of document of abandonment before decision of registration
SUBM Surrender of laid-open application requested